GlassScriptPhysician profile
Jennifer A Meitzner
NPI 1154515203
$12,850.73
in general payments reported to CMS, 2019-2025
31 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,166 · 2022: $2,726 · 2023: $2,491 · 2024: $2,877 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,556 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,556.42 |
| Education | $402.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,757.22 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,717.66 | 2021-2025 | |
| Abbvie INC. | $1,407.30 | 2021-2025 | |
| Janssen Biotech, INC. | $1,247.07 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $877.29 | 2021-2025 | |
| Galderma Laboratories, L.P. | $788.72 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Lilly USA, LLC | $766.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $744.63 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $701.92 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $513.56 | 2021-2025 | Dupixent |
| Ucb, INC. | $375.58 | 2023-2025 | Bimzelx |
| Pfizer INC. | $373.13 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $210.58 | 2021-2024 | Arazlo, Jublia, Cabtreo |
| Vyne Pharmaceuticals INC. | $190.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $144.98 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $141.90 | 2023-2025 | Vtama, Hadlima, Renflexis |
| Incyte Corporation | $139.51 | 2021-2023 | Opzelura |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Leo Pharma INC. | $107.54 | 2021-2025 | Adbry |
| Mayne Pharma Commercial LLC | $94.80 | 2022-2025 | |
| Dermavant Sciences, INC. | $82.56 | 2023-2024 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $76.31 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.81 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $53.41 | 2023-2025 | Zoryve |
| Dermira, INC. | $31.24 | 2021 | |
| Epi Health, LLC | $28.06 | 2021 | |
| Almirall LLC | $23.87 | 2022 | |
| Allergan, INC. | $18.55 | 2022 | |
| Biofrontera INC. | $18.04 | 2022 | |
| Lnhc, INC | $17.42 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $17.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Meitzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.